Investor's Business Daily on MSN7h
Novo Nordisk Dives 9%. Why Eli Lilly Now Has The Upper Hand.
Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.
Novo Nordisk under pressure as obesity drug disappoints in diabetes trial
Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.
Novo Nordisk shares fall on weight-loss drug trial
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
Novo Nordisk shares fall 5.4% after latest trial results for its next-generation weight loss drug
Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its ...
Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results
The pharmaceutical giant released fresh trial data showing the drug helped obese or overweight type 2 diabetics lose an ...
ROSEN, A LEADING AND RANKED FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
NEW YORK, NY / ACCESS Newswire / March 8, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers ...
Fierce Pharma3d
With blood and growth disorder bids panning out, Novo Nordisk plots path to rare disease leadership: exec
Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...
Endpoints News4d
No­vo Nordisk’s rare dis­ease ‘com­pa­ny with­in a com­pa­ny’ has an open goal in sick­le cell
Novo Nordisk's rare disease unit awaits Phase 3 data for etavopivat in sickle cell disease, aiming for 50% VOC reduction ...